{
    "info": {
        "nct_id": "NCT04468984",
        "official_title": "Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2), Incorporating Extension Arm C - Continued Access for Navitoclax to Roll Over Subjects From Studies M10-166, M16-109, M16-191, and M19-753",
        "inclusion_criteria": "* Must complete the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 on at least 4 out of the 7 days immediately prior to the date of randomization and must agree to collect MFSAF data daily by ePRO device during the study collection window.\n\n  -- Has at least 2 symptoms each with an average score >= 3 or an average total score of >= 12, as measured by the MFSAF v4.0.\n* Documented diagnosis of primary myelofibrosis (MF) as defined by the World Health Organization (WHO) classification, post polycythemia vera (PPV)-MF, or post essential thrombocytopenia (PET)-MF, characterized by bone marrow fibrosis grades 2 or 3.\n* Classified as intermediate-2 or high-risk MF, as defined by the Dynamic International Prognostic Scoring System Plus (DIPSS+).\n* Must currently be on treatment or have received prior treatment with a single Janus Kinase 2 (JAK2) inhibitor, ruxolitinib, and meet one of the following criteria (in addition to the minimum splenomegaly and symptom burden also required for eligibility):\n\n  * Treatment with ruxolitinib for >= 24 weeks that was stopped due to lack of spleen response (refractory), or loss of spleen response or symptom control after a previous response (relapsed), or was continued despite relapsed/refractory status.\n  * Treatment with ruxolitinib for < 24 weeks with documented disease progression while on therapy as defined by any of the following:\n\n    * Appearance of new splenomegaly that is palpable to at least 5 cm below the left costal margin (LCM) in participants with no evidence of splenomegaly prior to the initiation of ruxolitinib.\n    * A >= 100% increase in the palpable distance below the LCM in participants with measurable spleen distance 5 to 10 centimeters (cm) prior to the initiation of ruxolitinib.\n    * A >= 50% increase in the palpable distance below the LCM in participants with measurable spleen distance > 10 cm prior to the initiation of ruxolitinib.\n    * A spleen volume increase of >= 25% (as assessed by Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan) in participants with a spleen volume assessment prior to the initiation of ruxolitinib.\n  * Prior treatment with ruxolitinib of at least 10 mg twice daily (BID) for >= 28 days with intolerance defined as new RBC transfusion requirement (at least 2 units/month for 2 months) while receiving a total daily ruxolitinib dose of >= 30 mg but unable to reduce dose further due to lack of efficacy.\n\nNote: Participant must not require a ruxolitinib dose less than 10 mg BID (20 mg daily) due to prior history of ruxolitinibrelated ≥ Grade 3 toxicity.\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n* Splenomegaly defined as palpable spleen measurement >= 5 cm below left costal margin or spleen volume >= 450 cm3 as assessed centrally by MRI or CT scan.\n* Baseline platelet count >= 100 × 10^9/L.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Received prior treatment with a B-cell lymphoma 2 homology 3 (BH3)-mimetic compound, bromodomain and extra-terminal (BET) inhibitor, phosphoinositide 3- kinase and telomerase inhibitors (e.g., parsaclisib), prior use of > 1 JAK2 inhibitor or stem cell transplant.\n* Eligible for stem cell transplantation at the time of study entry.\n* Receiving medication that interferes with coagulation or platelet function within 3 days prior to the first dose of study drug or during the study treatment period except for low dose aspirin (up to 100 mg daily) and low molecular weight heparin (LMWH).\n* Receiving anticancer therapy for an active malignancy or MF including chemotherapy, radiation therapy, hormonal therapy such that at least 5 half-lives of that medication is completed at least 7 days prior to the first dose of study drug or within 30 days prior to first dose of study drug, whichever is shorter, and during the study treatment period (other than any overlapping therapy as part of the selected BAT).",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "-- Has at least 2 symptoms each with an average score >= 3 or an average total score of >= 12, as measured by the MFSAF v4.0.",
                "criterions": [
                    {
                        "exact_snippets": "at least 2 symptoms each with an average score >= 3 ... as measured by the MFSAF v4.0",
                        "criterion": "symptom severity (individual)",
                        "requirement": {
                            "requirement_type": "count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "symptoms"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at least 2 symptoms each with an average score >= 3 ... as measured by the MFSAF v4.0",
                        "criterion": "symptom severity (individual)",
                        "requirement": {
                            "requirement_type": "average score per symptom",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "at least 2 symptoms each with an average score >= 3 ... as measured by the MFSAF v4.0",
                        "criterion": "symptom severity (individual)",
                        "requirement": {
                            "requirement_type": "measurement instrument",
                            "expected_value": "MFSAF v4.0"
                        }
                    },
                    {
                        "exact_snippets": "average total score of >= 12, as measured by the MFSAF v4.0",
                        "criterion": "symptom severity (total score)",
                        "requirement": {
                            "requirement_type": "average total score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "average total score of >= 12, as measured by the MFSAF v4.0",
                        "criterion": "symptom severity (total score)",
                        "requirement": {
                            "requirement_type": "measurement instrument",
                            "expected_value": "MFSAF v4.0"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "at least 2 symptoms each with an average score >= 3 ... as measured by the MFSAF v4.0",
                                        "criterion": "symptom severity (individual)",
                                        "requirement": {
                                            "requirement_type": "count",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 2,
                                                "unit": "symptoms"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "at least 2 symptoms each with an average score >= 3 ... as measured by the MFSAF v4.0",
                                        "criterion": "symptom severity (individual)",
                                        "requirement": {
                                            "requirement_type": "average score per symptom",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 3,
                                                "unit": ""
                                            }
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "at least 2 symptoms each with an average score >= 3 ... as measured by the MFSAF v4.0",
                                "criterion": "symptom severity (individual)",
                                "requirement": {
                                    "requirement_type": "measurement instrument",
                                    "expected_value": "MFSAF v4.0"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "average total score of >= 12, as measured by the MFSAF v4.0",
                                "criterion": "symptom severity (total score)",
                                "requirement": {
                                    "requirement_type": "average total score",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 12,
                                        "unit": ""
                                    }
                                }
                            },
                            {
                                "exact_snippets": "average total score of >= 12, as measured by the MFSAF v4.0",
                                "criterion": "symptom severity (total score)",
                                "requirement": {
                                    "requirement_type": "measurement instrument",
                                    "expected_value": "MFSAF v4.0"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Treatment with ruxolitinib for < 24 weeks with documented disease progression while on therapy as defined by any of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Treatment with ruxolitinib for < 24 weeks",
                        "criterion": "treatment duration with ruxolitinib",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 24,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "documented disease progression while on therapy",
                        "criterion": "disease progression while on ruxolitinib therapy",
                        "requirement": {
                            "requirement_type": "progression_status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Treatment with ruxolitinib for < 24 weeks",
                        "criterion": "treatment duration with ruxolitinib",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 24,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "documented disease progression while on therapy",
                        "criterion": "disease progression while on ruxolitinib therapy",
                        "requirement": {
                            "requirement_type": "progression_status",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* A >= 50% increase in the palpable distance below the LCM in participants with measurable spleen distance > 10 cm prior to the initiation of ruxolitinib.",
                "criterions": [
                    {
                        "exact_snippets": "measurable spleen distance > 10 cm prior to the initiation of ruxolitinib",
                        "criterion": "measurable spleen distance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": ">= 50% increase in the palpable distance below the LCM",
                        "criterion": "palpable distance below the LCM",
                        "requirement": {
                            "requirement_type": "change from baseline",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "measurable spleen distance > 10 cm prior to the initiation of ruxolitinib",
                    "criterion": "measurable spleen distance",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "operator": ">",
                            "value": 10,
                            "unit": "cm"
                        }
                    }
                },
                "then_criteria": {
                    "exact_snippets": ">= 50% increase in the palpable distance below the LCM",
                    "criterion": "palpable distance below the LCM",
                    "requirement": {
                        "requirement_type": "change from baseline",
                        "expected_value": {
                            "operator": ">=",
                            "value": 50,
                            "unit": "%"
                        }
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Treatment with ruxolitinib for >= 24 weeks that was stopped due to lack of spleen response (refractory), or loss of spleen response or symptom control after a previous response (relapsed), or was continued despite relapsed/refractory status.",
                "criterions": [
                    {
                        "exact_snippets": "Treatment with ruxolitinib for >= 24 weeks",
                        "criterion": "treatment with ruxolitinib",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 24,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "stopped due to lack of spleen response (refractory)",
                        "criterion": "spleen response to ruxolitinib",
                        "requirement": {
                            "requirement_type": "response",
                            "expected_value": "lack of response (refractory)"
                        }
                    },
                    {
                        "exact_snippets": "loss of spleen response or symptom control after a previous response (relapsed)",
                        "criterion": "spleen response or symptom control after previous response to ruxolitinib",
                        "requirement": {
                            "requirement_type": "response",
                            "expected_value": "loss of response or symptom control (relapsed)"
                        }
                    },
                    {
                        "exact_snippets": "continued despite relapsed/refractory status",
                        "criterion": "treatment with ruxolitinib despite relapsed/refractory status",
                        "requirement": {
                            "requirement_type": "continuation despite status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Treatment with ruxolitinib for >= 24 weeks",
                        "criterion": "treatment with ruxolitinib",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 24,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "stopped due to lack of spleen response (refractory)",
                                "criterion": "spleen response to ruxolitinib",
                                "requirement": {
                                    "requirement_type": "response",
                                    "expected_value": "lack of response (refractory)"
                                }
                            },
                            {
                                "exact_snippets": "loss of spleen response or symptom control after a previous response (relapsed)",
                                "criterion": "spleen response or symptom control after previous response to ruxolitinib",
                                "requirement": {
                                    "requirement_type": "response",
                                    "expected_value": "loss of response or symptom control (relapsed)"
                                }
                            },
                            {
                                "exact_snippets": "continued despite relapsed/refractory status",
                                "criterion": "treatment with ruxolitinib despite relapsed/refractory status",
                                "requirement": {
                                    "requirement_type": "continuation despite status",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Appearance of new splenomegaly that is palpable to at least 5 cm below the left costal margin (LCM) in participants with no evidence of splenomegaly prior to the initiation of ruxolitinib.",
                "criterions": [
                    {
                        "exact_snippets": "Appearance of new splenomegaly",
                        "criterion": "splenomegaly",
                        "requirement": {
                            "requirement_type": "onset",
                            "expected_value": "new"
                        }
                    },
                    {
                        "exact_snippets": "palpable to at least 5 cm below the left costal margin (LCM)",
                        "criterion": "splenomegaly",
                        "requirement": {
                            "requirement_type": "palpable_extent",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "cm below LCM"
                            }
                        }
                    },
                    {
                        "exact_snippets": "participants with no evidence of splenomegaly prior to the initiation of ruxolitinib",
                        "criterion": "splenomegaly prior to ruxolitinib",
                        "requirement": {
                            "requirement_type": "evidence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Appearance of new splenomegaly",
                                "criterion": "splenomegaly",
                                "requirement": {
                                    "requirement_type": "onset",
                                    "expected_value": "new"
                                }
                            },
                            {
                                "exact_snippets": "palpable to at least 5 cm below the left costal margin (LCM)",
                                "criterion": "splenomegaly",
                                "requirement": {
                                    "requirement_type": "palpable_extent",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "cm below LCM"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "participants with no evidence of splenomegaly prior to the initiation of ruxolitinib",
                        "criterion": "splenomegaly prior to ruxolitinib",
                        "requirement": {
                            "requirement_type": "evidence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior treatment with ruxolitinib of at least 10 mg twice daily (BID) for >= 28 days with intolerance defined as new RBC transfusion requirement (at least 2 units/month for 2 months) while receiving a total daily ruxolitinib dose of >= 30 mg but unable to reduce dose further due to lack of efficacy.",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with ruxolitinib of at least 10 mg twice daily (BID) for >= 28 days",
                        "criterion": "prior ruxolitinib treatment",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ruxolitinib of at least 10 mg twice daily (BID) for >= 28 days",
                        "criterion": "prior ruxolitinib treatment",
                        "requirement": {
                            "requirement_type": "frequency",
                            "expected_value": "twice daily (BID)"
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ruxolitinib of at least 10 mg twice daily (BID) for >= 28 days",
                        "criterion": "prior ruxolitinib treatment",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "intolerance defined as new RBC transfusion requirement (at least 2 units/month for 2 months) while receiving a total daily ruxolitinib dose of >= 30 mg",
                        "criterion": "ruxolitinib intolerance (RBC transfusion requirement)",
                        "requirement": {
                            "requirement_type": "RBC transfusion requirement",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "units/month"
                            }
                        }
                    },
                    {
                        "exact_snippets": "intolerance defined as new RBC transfusion requirement (at least 2 units/month for 2 months) while receiving a total daily ruxolitinib dose of >= 30 mg",
                        "criterion": "ruxolitinib intolerance (RBC transfusion requirement)",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "intolerance defined as new RBC transfusion requirement (at least 2 units/month for 2 months) while receiving a total daily ruxolitinib dose of >= 30 mg",
                        "criterion": "ruxolitinib intolerance (RBC transfusion requirement)",
                        "requirement": {
                            "requirement_type": "concurrent ruxolitinib dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mg (total daily)"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unable to reduce dose further due to lack of efficacy",
                        "criterion": "inability to reduce ruxolitinib dose",
                        "requirement": {
                            "requirement_type": "dose reduction possible",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "unable to reduce dose further due to lack of efficacy",
                        "criterion": "inability to reduce ruxolitinib dose",
                        "requirement": {
                            "requirement_type": "reason",
                            "expected_value": "lack of efficacy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Prior treatment with ruxolitinib of at least 10 mg twice daily (BID) for >= 28 days",
                                "criterion": "prior ruxolitinib treatment",
                                "requirement": {
                                    "requirement_type": "dose",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 10,
                                        "unit": "mg"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Prior treatment with ruxolitinib of at least 10 mg twice daily (BID) for >= 28 days",
                                "criterion": "prior ruxolitinib treatment",
                                "requirement": {
                                    "requirement_type": "frequency",
                                    "expected_value": "twice daily (BID)"
                                }
                            },
                            {
                                "exact_snippets": "Prior treatment with ruxolitinib of at least 10 mg twice daily (BID) for >= 28 days",
                                "criterion": "prior ruxolitinib treatment",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "and_criteria": [
                                            {
                                                "exact_snippets": "intolerance defined as new RBC transfusion requirement (at least 2 units/month for 2 months) while receiving a total daily ruxolitinib dose of >= 30 mg",
                                                "criterion": "ruxolitinib intolerance (RBC transfusion requirement)",
                                                "requirement": {
                                                    "requirement_type": "RBC transfusion requirement",
                                                    "expected_value": {
                                                        "operator": ">=",
                                                        "value": 2,
                                                        "unit": "units/month"
                                                    }
                                                }
                                            },
                                            {
                                                "exact_snippets": "intolerance defined as new RBC transfusion requirement (at least 2 units/month for 2 months) while receiving a total daily ruxolitinib dose of >= 30 mg",
                                                "criterion": "ruxolitinib intolerance (RBC transfusion requirement)",
                                                "requirement": {
                                                    "requirement_type": "duration",
                                                    "expected_value": {
                                                        "operator": ">=",
                                                        "value": 2,
                                                        "unit": "months"
                                                    }
                                                }
                                            },
                                            {
                                                "exact_snippets": "intolerance defined as new RBC transfusion requirement (at least 2 units/month for 2 months) while receiving a total daily ruxolitinib dose of >= 30 mg",
                                                "criterion": "ruxolitinib intolerance (RBC transfusion requirement)",
                                                "requirement": {
                                                    "requirement_type": "concurrent ruxolitinib dose",
                                                    "expected_value": {
                                                        "operator": ">=",
                                                        "value": 30,
                                                        "unit": "mg (total daily)"
                                                    }
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "and_criteria": [
                                            {
                                                "exact_snippets": "unable to reduce dose further due to lack of efficacy",
                                                "criterion": "inability to reduce ruxolitinib dose",
                                                "requirement": {
                                                    "requirement_type": "dose reduction possible",
                                                    "expected_value": false
                                                }
                                            },
                                            {
                                                "exact_snippets": "unable to reduce dose further due to lack of efficacy",
                                                "criterion": "inability to reduce ruxolitinib dose",
                                                "requirement": {
                                                    "requirement_type": "reason",
                                                    "expected_value": "lack of efficacy"
                                                }
                                            }
                                        ]
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Baseline platelet count >= 100 × 10^9/L.",
                "criterions": [
                    {
                        "exact_snippets": "Baseline platelet count >= 100 × 10^9/L.",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "× 10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Baseline platelet count >= 100 × 10^9/L.",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "× 10^9/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Documented diagnosis of primary myelofibrosis (MF) as defined by the World Health Organization (WHO) classification, post polycythemia vera (PPV)-MF, or post essential thrombocytopenia (PET)-MF, characterized by bone marrow fibrosis grades 2 or 3.",
                "criterions": [
                    {
                        "exact_snippets": "Documented diagnosis of primary myelofibrosis (MF) as defined by the World Health Organization (WHO) classification",
                        "criterion": "primary myelofibrosis diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Documented diagnosis of primary myelofibrosis (MF) as defined by the World Health Organization (WHO) classification",
                        "criterion": "primary myelofibrosis diagnosis",
                        "requirement": {
                            "requirement_type": "definition standard",
                            "expected_value": "World Health Organization (WHO) classification"
                        }
                    },
                    {
                        "exact_snippets": "post polycythemia vera (PPV)-MF",
                        "criterion": "post polycythemia vera myelofibrosis diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "post essential thrombocytopenia (PET)-MF",
                        "criterion": "post essential thrombocytopenia myelofibrosis diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "characterized by bone marrow fibrosis grades 2 or 3",
                        "criterion": "bone marrow fibrosis grade",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Documented diagnosis of primary myelofibrosis (MF) as defined by the World Health Organization (WHO) classification",
                                        "criterion": "primary myelofibrosis diagnosis",
                                        "requirement": {
                                            "requirement_type": "diagnosis",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "Documented diagnosis of primary myelofibrosis (MF) as defined by the World Health Organization (WHO) classification",
                                        "criterion": "primary myelofibrosis diagnosis",
                                        "requirement": {
                                            "requirement_type": "definition standard",
                                            "expected_value": "World Health Organization (WHO) classification"
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "post polycythemia vera (PPV)-MF",
                                "criterion": "post polycythemia vera myelofibrosis diagnosis",
                                "requirement": {
                                    "requirement_type": "diagnosis",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "post essential thrombocytopenia (PET)-MF",
                                "criterion": "post essential thrombocytopenia myelofibrosis diagnosis",
                                "requirement": {
                                    "requirement_type": "diagnosis",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "characterized by bone marrow fibrosis grades 2 or 3",
                        "criterion": "bone marrow fibrosis grade",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Must complete the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 on at least 4 out of the 7 days immediately prior to the date of randomization and must agree to collect MFSAF data daily by ePRO device during the study collection window.",
                "criterions": [
                    {
                        "exact_snippets": "Must complete the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 on at least 4 out of the 7 days immediately prior to the date of randomization",
                        "criterion": "MFSAF v4.0 completion",
                        "requirement": {
                            "requirement_type": "completion_frequency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "must agree to collect MFSAF data daily by ePRO device during the study collection window",
                        "criterion": "agreement to daily MFSAF data collection by ePRO",
                        "requirement": {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must agree to collect MFSAF data daily by ePRO device during the study collection window",
                        "criterion": "agreement to daily MFSAF data collection by ePRO",
                        "requirement": {
                            "requirement_type": "collection_frequency",
                            "expected_value": "daily"
                        }
                    },
                    {
                        "exact_snippets": "must agree to collect MFSAF data daily by ePRO device during the study collection window",
                        "criterion": "agreement to daily MFSAF data collection by ePRO",
                        "requirement": {
                            "requirement_type": "collection_method",
                            "expected_value": "ePRO device"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must complete the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 on at least 4 out of the 7 days immediately prior to the date of randomization",
                        "criterion": "MFSAF v4.0 completion",
                        "requirement": {
                            "requirement_type": "completion_frequency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "must agree to collect MFSAF data daily by ePRO device during the study collection window",
                                "criterion": "agreement to daily MFSAF data collection by ePRO",
                                "requirement": {
                                    "requirement_type": "agreement",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "must agree to collect MFSAF data daily by ePRO device during the study collection window",
                                "criterion": "agreement to daily MFSAF data collection by ePRO",
                                "requirement": {
                                    "requirement_type": "collection_frequency",
                                    "expected_value": "daily"
                                }
                            },
                            {
                                "exact_snippets": "must agree to collect MFSAF data daily by ePRO device during the study collection window",
                                "criterion": "agreement to daily MFSAF data collection by ePRO",
                                "requirement": {
                                    "requirement_type": "collection_method",
                                    "expected_value": "ePRO device"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* A >= 100% increase in the palpable distance below the LCM in participants with measurable spleen distance 5 to 10 centimeters (cm) prior to the initiation of ruxolitinib.",
                "criterions": [
                    {
                        "exact_snippets": "A >= 100% increase in the palpable distance below the LCM",
                        "criterion": "palpable spleen distance below the LCM",
                        "requirement": {
                            "requirement_type": "change from baseline",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "A >= 100% increase in the palpable distance below the LCM",
                        "criterion": "palpable spleen distance below the LCM",
                        "requirement": {
                            "requirement_type": "direction of change",
                            "expected_value": "increase"
                        }
                    },
                    {
                        "exact_snippets": "measurable spleen distance 5 to 10 centimeters (cm) prior to the initiation of ruxolitinib",
                        "criterion": "spleen distance prior to ruxolitinib",
                        "requirement": {
                            "requirement_type": "measurable",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "measurable spleen distance 5 to 10 centimeters (cm) prior to the initiation of ruxolitinib",
                        "criterion": "spleen distance prior to ruxolitinib",
                        "requirement": {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "cm"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": "cm"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "A >= 100% increase in the palpable distance below the LCM",
                                "criterion": "palpable spleen distance below the LCM",
                                "requirement": {
                                    "requirement_type": "change from baseline",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 100,
                                        "unit": "%"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "A >= 100% increase in the palpable distance below the LCM",
                                "criterion": "palpable spleen distance below the LCM",
                                "requirement": {
                                    "requirement_type": "direction of change",
                                    "expected_value": "increase"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "measurable spleen distance 5 to 10 centimeters (cm) prior to the initiation of ruxolitinib",
                                "criterion": "spleen distance prior to ruxolitinib",
                                "requirement": {
                                    "requirement_type": "measurable",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "measurable spleen distance 5 to 10 centimeters (cm) prior to the initiation of ruxolitinib",
                                "criterion": "spleen distance prior to ruxolitinib",
                                "requirement": {
                                    "requirement_type": "range",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 5,
                                                "unit": "cm"
                                            },
                                            {
                                                "operator": "<=",
                                                "value": 10,
                                                "unit": "cm"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Eligible for stem cell transplantation at the time of study entry.",
                "criterions": [
                    {
                        "exact_snippets": "Eligible for stem cell transplantation at the time of study entry.",
                        "criterion": "stem cell transplantation eligibility",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Eligible for stem cell transplantation at the time of study entry.",
                        "criterion": "stem cell transplantation eligibility",
                        "requirement": {
                            "requirement_type": "timepoint",
                            "expected_value": "at the time of study entry"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Eligible for stem cell transplantation at the time of study entry.",
                                "criterion": "stem cell transplantation eligibility",
                                "requirement": {
                                    "requirement_type": "eligibility",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Eligible for stem cell transplantation at the time of study entry.",
                                "criterion": "stem cell transplantation eligibility",
                                "requirement": {
                                    "requirement_type": "timepoint",
                                    "expected_value": "at the time of study entry"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Received prior treatment with a B-cell lymphoma 2 homology 3 (BH3)-mimetic compound, bromodomain and extra-terminal (BET) inhibitor, phosphoinositide 3- kinase and telomerase inhibitors (e.g., parsaclisib), prior use of > 1 JAK2 inhibitor or stem cell transplant.",
                "criterions": [
                    {
                        "exact_snippets": "Received prior treatment with a B-cell lymphoma 2 homology 3 (BH3)-mimetic compound",
                        "criterion": "prior treatment with BH3-mimetic compound",
                        "requirement": {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Received prior treatment with ... bromodomain and extra-terminal (BET) inhibitor",
                        "criterion": "prior treatment with BET inhibitor",
                        "requirement": {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Received prior treatment with ... phosphoinositide 3- kinase ... inhibitors (e.g., parsaclisib)",
                        "criterion": "prior treatment with phosphoinositide 3-kinase inhibitor",
                        "requirement": {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Received prior treatment with ... telomerase inhibitors",
                        "criterion": "prior treatment with telomerase inhibitor",
                        "requirement": {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior use of > 1 JAK2 inhibitor",
                        "criterion": "prior use of JAK2 inhibitors",
                        "requirement": {
                            "requirement_type": "number of prior JAK2 inhibitors used",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "inhibitors"
                            }
                        }
                    },
                    {
                        "exact_snippets": "prior ... stem cell transplant",
                        "criterion": "prior stem cell transplant",
                        "requirement": {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Received prior treatment with a B-cell lymphoma 2 homology 3 (BH3)-mimetic compound",
                        "criterion": "prior treatment with BH3-mimetic compound",
                        "requirement": {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Received prior treatment with ... bromodomain and extra-terminal (BET) inhibitor",
                        "criterion": "prior treatment with BET inhibitor",
                        "requirement": {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Received prior treatment with ... phosphoinositide 3- kinase ... inhibitors (e.g., parsaclisib)",
                        "criterion": "prior treatment with phosphoinositide 3-kinase inhibitor",
                        "requirement": {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Received prior treatment with ... telomerase inhibitors",
                        "criterion": "prior treatment with telomerase inhibitor",
                        "requirement": {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior use of > 1 JAK2 inhibitor",
                        "criterion": "prior use of JAK2 inhibitors",
                        "requirement": {
                            "requirement_type": "number of prior JAK2 inhibitors used",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "inhibitors"
                            }
                        }
                    },
                    {
                        "exact_snippets": "prior ... stem cell transplant",
                        "criterion": "prior stem cell transplant",
                        "requirement": {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Classified as intermediate-2 or high-risk MF, as defined by the Dynamic International Prognostic Scoring System Plus (DIPSS+).",
                "criterions": [
                    {
                        "exact_snippets": "Classified as intermediate-2 or high-risk MF, as defined by the Dynamic International Prognostic Scoring System Plus (DIPSS+)",
                        "criterion": "myelofibrosis (MF) risk classification",
                        "requirement": {
                            "requirement_type": "risk category",
                            "expected_value": [
                                "intermediate-2",
                                "high-risk"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Classified as intermediate-2 or high-risk MF, as defined by the Dynamic International Prognostic Scoring System Plus (DIPSS+)",
                        "criterion": "myelofibrosis (MF) risk classification",
                        "requirement": {
                            "requirement_type": "scoring system",
                            "expected_value": "Dynamic International Prognostic Scoring System Plus (DIPSS+)"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Splenomegaly defined as palpable spleen measurement >= 5 cm below left costal margin or spleen volume >= 450 cm3 as assessed centrally by MRI or CT scan.",
                "criterions": [
                    {
                        "exact_snippets": "Splenomegaly defined as palpable spleen measurement >= 5 cm below left costal margin",
                        "criterion": "palpable spleen measurement",
                        "requirement": {
                            "requirement_type": "size_below_left_costal_margin",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "spleen volume >= 450 cm3 as assessed centrally by MRI or CT scan",
                        "criterion": "spleen volume",
                        "requirement": {
                            "requirement_type": "volume",
                            "expected_value": {
                                "operator": ">=",
                                "value": 450,
                                "unit": "cm3"
                            }
                        }
                    },
                    {
                        "exact_snippets": "spleen volume >= 450 cm3 as assessed centrally by MRI or CT scan",
                        "criterion": "spleen volume",
                        "requirement": {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "MRI",
                                "CT scan"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* A spleen volume increase of >= 25% (as assessed by Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan) in participants with a spleen volume assessment prior to the initiation of ruxolitinib.",
                "criterions": [
                    {
                        "exact_snippets": "A spleen volume increase of >= 25%",
                        "criterion": "spleen volume increase",
                        "requirement": {
                            "requirement_type": "change from baseline",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "A spleen volume increase of >= 25%",
                        "criterion": "spleen volume increase",
                        "requirement": {
                            "requirement_type": "assessment method",
                            "expected_value": [
                                "Magnetic Resonance Imaging [MRI]",
                                "Computed Tomography [CT] scan"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "participants with a spleen volume assessment prior to the initiation of ruxolitinib",
                        "criterion": "spleen volume assessment prior to ruxolitinib initiation",
                        "requirement": {
                            "requirement_type": "assessment prior to treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Must currently be on treatment or have received prior treatment with a single Janus Kinase 2 (JAK2) inhibitor, ruxolitinib, and meet one of the following criteria (in addition to the minimum splenomegaly and symptom burden also required for eligibility):",
                "criterions": [
                    {
                        "exact_snippets": "Must currently be on treatment or have received prior treatment with a single Janus Kinase 2 (JAK2) inhibitor, ruxolitinib",
                        "criterion": "JAK2 inhibitor (ruxolitinib) treatment history",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": [
                                "currently on treatment",
                                "prior treatment"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Must currently be on treatment or have received prior treatment with a single Janus Kinase 2 (JAK2) inhibitor, ruxolitinib",
                        "criterion": "JAK2 inhibitor (ruxolitinib) treatment history",
                        "requirement": {
                            "requirement_type": "number of JAK2 inhibitors",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "inhibitor"
                            }
                        }
                    },
                    {
                        "exact_snippets": "minimum splenomegaly ... required for eligibility",
                        "criterion": "splenomegaly",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "minimum"
                        }
                    },
                    {
                        "exact_snippets": "minimum ... symptom burden also required for eligibility",
                        "criterion": "symptom burden",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "minimum"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "Note: Participant must not require a ruxolitinib dose less than 10 mg BID (20 mg daily) due to prior history of ruxolitinibrelated ≥ Grade 3 toxicity.",
                "criterions": [
                    {
                        "exact_snippets": "Participant must not require a ruxolitinib dose less than 10 mg BID (20 mg daily) due to prior history of ruxolitinibrelated ≥ Grade 3 toxicity.",
                        "criterion": "required ruxolitinib dose",
                        "requirement": {
                            "requirement_type": "minimum dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mg BID"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Participant must not require a ruxolitinib dose less than 10 mg BID (20 mg daily) due to prior history of ruxolitinibrelated ≥ Grade 3 toxicity.",
                        "criterion": "required ruxolitinib dose",
                        "requirement": {
                            "requirement_type": "reason for dose reduction",
                            "expected_value": "prior history of ruxolitinibrelated ≥ Grade 3 toxicity"
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "and_criteria": [
                        {
                            "and_criteria": [
                                {
                                    "exact_snippets": "Participant must not require a ruxolitinib dose less than 10 mg BID (20 mg daily) due to prior history of ruxolitinibrelated \u001e Grade 3 toxicity.",
                                    "criterion": "required ruxolitinib dose",
                                    "requirement": {
                                        "requirement_type": "minimum dose",
                                        "expected_value": {
                                            "operator": "<",
                                            "value": 10,
                                            "unit": "mg BID"
                                        }
                                    }
                                },
                                {
                                    "exact_snippets": "Participant must not require a ruxolitinib dose less than 10 mg BID (20 mg daily) due to prior history of ruxolitinibrelated \u001e Grade 3 toxicity.",
                                    "criterion": "required ruxolitinib dose",
                                    "requirement": {
                                        "requirement_type": "reason for dose reduction",
                                        "expected_value": "prior history of ruxolitinibrelated \u001e Grade 3 toxicity"
                                    }
                                }
                            ]
                        }
                    ]
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Receiving medication that interferes with coagulation or platelet function within 3 days prior to the first dose of study drug or during the study treatment period except for low dose aspirin (up to 100 mg daily) and low molecular weight heparin (LMWH).",
                "criterions": [
                    {
                        "exact_snippets": "Receiving medication that interferes with coagulation or platelet function within 3 days prior to the first dose of study drug or during the study treatment period",
                        "criterion": "medication that interferes with coagulation or platelet function",
                        "requirement": {
                            "requirement_type": "exposure timing",
                            "expected_value": [
                                "within 3 days prior to the first dose of study drug",
                                "during the study treatment period"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Receiving medication that interferes with coagulation or platelet function within 3 days prior to the first dose of study drug or during the study treatment period",
                        "criterion": "medication that interferes with coagulation or platelet function",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Receiving anticancer therapy for an active malignancy or MF including chemotherapy, radiation therapy, hormonal therapy such that at least 5 half-lives of that medication is completed at least 7 days prior to the first dose of study drug or within 30 days prior to first dose of study drug, whichever is shorter, and during the study treatment period (other than any overlapping therapy as part of the selected BAT).",
                "criterions": [
                    {
                        "exact_snippets": "Receiving anticancer therapy for an active malignancy or MF including chemotherapy, radiation therapy, hormonal therapy",
                        "criterion": "anticancer therapy",
                        "requirement": {
                            "requirement_type": "receiving",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Receiving anticancer therapy for an active malignancy or MF including chemotherapy, radiation therapy, hormonal therapy",
                        "criterion": "anticancer therapy",
                        "requirement": {
                            "requirement_type": "therapy_type",
                            "expected_value": [
                                "chemotherapy",
                                "radiation therapy",
                                "hormonal therapy"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "at least 5 half-lives of that medication is completed at least 7 days prior to the first dose of study drug or within 30 days prior to first dose of study drug, whichever is shorter",
                        "criterion": "washout period for prior anticancer therapy",
                        "requirement": {
                            "requirement_type": "completion_time_before_study_drug",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 7,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 30,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "during the study treatment period (other than any overlapping therapy as part of the selected BAT)",
                        "criterion": "concurrent anticancer therapy during study",
                        "requirement": {
                            "requirement_type": "concurrent_therapy_allowed",
                            "expected_value": "only overlapping therapy as part of the selected BAT"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}